{"nctId":"NCT01095003","briefTitle":"Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer","startDateStruct":{"date":"2009-05"},"conditions":["Breast Cancer"],"count":770,"armGroups":[{"label":"Vinflunine plus Capecitabine","type":"EXPERIMENTAL","interventionNames":["Drug: Vinflunine plus Capecitabine"]},{"label":"Capecitabine single-agent","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Capecitabine"]}],"interventions":[{"name":"Vinflunine plus Capecitabine","otherNames":["JAVLOR","L00070 IN"]},{"name":"Capecitabine","otherNames":["XELODA"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* female patients\n* 21 years of age or older\n* histologically/cytologically confirmed carcinoma of the breast\n* documented locally recurrent or metastatic disease not amenable to curative surgery or radiotherapy\n* either one, two or three prior chemotherapy regimens\n* prior treatments including both an anthracycline and a taxane and patient no longer candidate for these drugs\n* measurable or non-measurable disease according to RECIST 1.1\n* Karnofsky performance score of at least 70 %\n* adequate haematological, hepatic and renal functions\n* ECG without clinically relevant abnormality\n\nExclusion Criteria:\n\n* known or clinical evidence of brain metastasis or leptomeningeal involvement\n* pulmonary lymphangitis or symptomatic pleural effusion\n* any serious, concurrent uncontrolled medical disorder\n* history of second primary malignancy\n* preexisting motor/sensory peripheral neuropathy\n* known history of HIV infection\n* prior therapy with capecitabine and/or vinca-alkaloids\n* history of severe hypersensitivity to vinca alkaloids and/or to fluoropyrimidine or contra indication to any of these drugs\n* known or suspected dihydropyrimidine dehydrogenase (DPD) deficiency\n* pregnancy or breast feeding","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"21 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival","description":"PFS is defined as time from date of randomization to date of the first documentation of objective tumor progression (according to the Independent Response Review Committee (IRC) and based on RECIST version 1.1) or death due to any cause.\n\nThe PFS was primarily analysed in the Intent-to-treat (ITT) population. Patients lost to follow-up, or without a known record of progression or death at time of analysis had the progression-free survival censored at the date of last tumour assessment or the date of last contact of a follow-up showing no progression, whichever occurs last.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null},{"groupId":"OG001","value":"4.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"The overall survival (OS) was defined as the duration between the date of randomisation and the date of death from any cause. The OS analysis was performed in the ITT population and the eligible and per protocol populations once the required number of events (631 deaths) was observed Patients lost to follow-up, or without a known record of death at time of analysis had the OS censored at the date of last contact.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.9","spread":null},{"groupId":"OG001","value":"11.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate (ORR)","description":"ORR defined as documentation of complete or partial response that was subsequently confirmed to first documentation of disease progression or to death due to any cause, whichever occurred first.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.9","spread":null},{"groupId":"OG001","value":"17.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Control Rate","description":"Disease control rate defined (DCR) as the sum of confirmed complete response, confirmed partial response and stabilisation rate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.3","spread":null},{"groupId":"OG001","value":"47.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response","description":"Measured from the first time that measurement criteria were first met for objective response (documented CR or PR) until recurrence/progression or death whatever the cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.3","spread":null},{"groupId":"OG001","value":"47.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":107,"n":383},"commonTop":["PPES","Nausea","Fatigue","Diarrhoea","Abdominal pain"]}}}